Abcellera Biologics Inc
NASDAQ:ABCL

Watchlist Manager
Abcellera Biologics Inc Logo
Abcellera Biologics Inc
NASDAQ:ABCL
Watchlist
Price: 2.57 USD -1.15% Market Closed
Market Cap: 765.8m USD

Wall Street
Price Targets

ABCL Price Targets Summary
Abcellera Biologics Inc

Wall Street analysts forecast ABCL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ABCL is 12.24 USD with a low forecast of 5.05 USD and a high forecast of 29.4 USD.

Lowest
Price Target
5.05 USD
96% Upside
Average
Price Target
12.24 USD
376% Upside
Highest
Price Target
29.4 USD
1 044% Upside
Abcellera Biologics Inc Competitors:
Price Targets
CDXS
Codexis Inc
231% Upside
CGEN
Compugen Ltd
227% Upside
AZTA
Azenta Inc
88% Upside
301333
R&G PharmaStudies Co Ltd
53% Upside
A
Agilent Technologies Inc
37% Upside
DIM
Sartorius Stedim Biotech SA
26% Upside
DIVISLAB
Divi's Laboratories Ltd
6% Downside
4880
CellSource Co Ltd
37% Upside

Revenue
Forecast

Revenue Estimate
Abcellera Biologics Inc

For the last 5 years the compound annual growth rate for Abcellera Biologics Inc's revenue is 20%. The projected CAGR for the next 3 years is 24%.

20%
Past Growth
24%
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Abcellera Biologics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Net Income
Forecast

Net Income Estimate
Abcellera Biologics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-10%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ABCL's stock price target?
Price Target
12.24 USD

According to Wall Street analysts, the average 1-year price target for ABCL is 12.24 USD with a low forecast of 5.05 USD and a high forecast of 29.4 USD.

What is Abcellera Biologics Inc's Revenue forecast?
Projected CAGR
24%

For the last 5 years the compound annual growth rate for Abcellera Biologics Inc's revenue is 20%. The projected CAGR for the next 3 years is 24%.

Back to Top